|本期目录/Table of Contents|

[1]薛清,李宁,褚恒,等.主动脉瓣机械瓣置换术后患者妊娠期抗凝治疗的前瞻性研究[J].国际心血管病杂志,2018,01:54-57.
　XUE Qing,LI Ning,CHU Heng,et al.Prospective study for anticoagulant therapy throughout pregnancy in patients after mechanical aortic valve replacement[J].International Journal of Cardiovascular Disease,2018,01:54-57.
点击复制

主动脉瓣机械瓣置换术后患者妊娠期抗凝治疗的前瞻性研究(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2018年01期
页码:
54-57
栏目:
临床研究
出版日期:
2018-01-25

文章信息/Info

Title:
Prospective study for anticoagulant therapy throughout pregnancy in patients after mechanical aortic valve replacement
作者:
薛清; 李宁; 褚恒; 韩林; 徐志云
200433 上海,第二军医大学附属长海医院心血管外科
Author(s):
XUE Qing;  LI Ning; CHU Heng;  HAN Lin;  XU Zhiyun.
Department of Cardiovascular Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
关键词:
主动脉瓣置换术;  机械瓣;  妊娠;  华法林
Keywords:
Aortic valve replacement;  Mechanical heart valve prosthesis;  Pregnancy;  Warfarin
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2018.01.014
文献标识码:
-
摘要:
目的:研究主动脉瓣机械瓣置换术后患者妊娠期的抗凝方案。方法:将2013年1月至2017年1月在长海医院进行产检的主动脉瓣机械瓣置换术后妊娠患者120例随机分为4组,分别选用不同的抗凝方案:A组全孕期口服国产华法林; B组孕12周前皮下注射低分子肝素钙,孕12周后口服国产华法林; C组全孕期口服进口华法林; D组孕12周前皮下注射低分子肝素钙,孕12周后口服进口华法林。各组患者国际标准化比值均控制在1.5～2.0。结果:(1)C组和D组服用华法林的剂量明显低于A组和B组。(2)4组产妇流产、早产、产后出血、
Abstract:
Objective:To explore and discuss the anticoagulant therapy throughout pregnancy in patients with mechanical aortic valve replacement.Methods:120 pregnant patients after mechanical aortic valve replacement were randomly divided into 4 groups according to d

参考文献/References

[1] Samiei N, Kashfi F, Khamoushi A, et al. Pregnancy outcome after mechanical mitral valve replacement: a prospective study[J]. J Tehran Heart Cent,2012,7(3):117-120.
[2] Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis[J]. Interact Cardiovasc Thorac Surg, 2014,18(6):797-806.
[3] Toyoda K. Antithrombotic therapy for pregnant women[J]. Neurol Med Chir(Tokyo), 2013, 53(8):526-530.
[4] Pieper PG. Use of medication for cardiovascular disease during pregnancy[J]. Nat Rev Cardiol, 2015,12(12):718-729.
[5] McLintock C. Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves[J]. Best Pract Res Clin Obstet Gynaecol, 2014, 28(4):519-536.
[6] Fogerty AE. Challenges of anticoagulation therapy in pregnancy[J]. Curr Treat Options Cardiovasc Med, 2017, 19(10):76.
[7] Ayad SW, Hassanein MM, Mohamed EA,et al. Maternal and fetal outcomes in pregnant women with a prosthetic mechanical heart valve[J]. Clin Med Insights Cardiol, 2016, 10:11-17.
[8] D’Souza R, Silversides CK, McLintock C. Optimal anticoagulation for pregnant women with mechanical heart valves[J]. Semin Thromb Hemost, 2016, 42(7):798-804.
[9] Stout MJ, Odibo AO. Anticoagulation in pregnant patients with mechanical heart valves: clinical considerations[J]. Clin Lab Med, 2013, 33(2):357-365.
[10] Vijayan V, Rachel T. Pregnancy outcomes compared in women with mechanical heart valve replacements anticoagulated with warfarin and enoxaparin in pregnancy[J]. Med J Malaysia, 2012, 67(6):591-594.
[11] Kanhere AV, Kanhere VM. Pregnancy after cardiac surgery[J]. J Obstet Gynaecol India, 2016, 66(1):10-15.
[12] Monteiro AV, Rebelo J, Patricio L, et al. Ten years’ experience of pregnancy outcome in women with cardiac valvulopathies: are valve prostheses worst?[J]. J Heart Valve Dis, 2015, 24(3):368-375.
[13] Schwartzenberg S, Perlman S, Levy R, et al. Mechanical heart valve thrombosis in pregnancy[J]. J Heart Valve Dis, 2013, 22(4):603-606.
[14] Singh N, Varshney P, Tripathi R, et al. Safety and efficacy of low molecular weight heparin therapy during pregnancy: three year experience at a tertiary care center[J]. J Obstet Gynaecol India, 2013, 63(6):373-377.
[15] Garcez JD, Rosa VE, Lopes AS, et al. Patient management with metallic valve prosthesis during pregnancy and postpartum period[J].Arq Bras Cardiol, 2015, 105(4):426-429.
[16] Silveira DB, da Rosa EB, de Mattos VF, et al. Importance of a multidisciplinary approach and monitoring in fetal warfarin syndrome[J]. Am J Med Genet A, 2015, 167(6): 1294-1299.
[17] Arioli F, D’Arbela PG, Aloi F, et al. Prosthetic thrombosis and pregnancy on warfarin: debate on mechanical mitral valve replacement in sub-Saharan Africa based on a case report[J]. Int J Cardiol, 2014, 176(3):e86-e88.
[18] Senol U, Ulus T, Birdane A, et al. The use of low molecular weight heparin during pregnancy in patients with mechanical heart valves carries potential risk for valve thrombosis: a report of three cases[J]. Turk Kardiyol Dern Ars, 2014, 42(3):294-298.
[19] Basu S, Aggarwal P, Kakani N, et al. Low-dose maternal warfarin intake resulting in fetal warfarin syndrome: in search for a safe anticoagulant regimen during pregnancy[J].Birth Defects Res A Clin Mol Teratol,2016,106(2):142-147.
[20] Tanaka H, Tanaka K, Kamiya C, et al. Analysis of anticoagulant therapy by unfractionated heparin during pregnancy after mechanical valve replacement[J]. Circ J, 2014, 78(4):878-881.

备注/Memo

备注/Memo:
基金项目:国家科技部重点研发计划(2016YFC1100900); 国家自然科学基金(81770383)通信作者:韩林,Email:xq9911310@163.com
更新日期/Last Update: 2018-04-01